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Perceived vocal morbidity in a problem asthma clinic
A E STANTON, C SELLARS*, K MACKENZIE†, A MCCONNACHIE‡, C E BUCKNALL
Abstract
Aims: Asthma treatment has the potential to affect patients’ voices. We undertook detailed
characterisation of voice morbidity in patients attending a problem asthma clinic, and we determined
how patients’ perceptions related to objective assessment by an experienced observer.
Methods: Forty-three patients took part in the study. Subjects completed the self-administered voice
symptom score (VoiSS) questionnaire and underwent digital voice recording. These voice recordings
were scored using the grade–roughness–breathiness–asthenicity–strain system (GRBAS). Laryngoscopy
was also performed.
Results: The median VoiSS was 26 (range three to 83). VoiSS were significantly lower in the 17 patients
with normal laryngeal structure and function (range four to 46; median 22), compared with the 26
patients with functional or structural laryngeal abnormality (range three to 83; median 33) (95 per cent
confidence intervals for difference 0.0–21.0; p ¼ 0.044). The overall grade score for the GRBAS scale did
not differ between these two groups, and only 13 patients had a GRBAS score of one or more,
recognised as indicating a voice problem. There were positive correlations between related GRBAS score
and voice symptom score subscales. Although voice symptom scores were significantly more abnormal in
patients with structural and functional abnormalities, this score performed only moderately well as a
predictive tool (sensitivity 54 per cent; specificity 71 per cent). Nevertheless, the voice symptom score
performed as well as the more labour-intensive GRBAS score (sensitivity 57 per cent; specificity 60 per
cent). Patients’ inhaled corticosteroid dose (median dose 1000 mg beclomethasone dipropionate or
equivalent) had a statistically significant relationship with their overall grade score for the GRBAS scale
(r ¼ 0.56; p, 0.001), but not with their VoiSS. Only one patient had evidence of laryngeal candidiasis,
and only two had any evidence of abnormality suggesting steroid-induced myopathy.
Conclusions: Vocal morbidity is common in patients with asthma, and should not be immediately
attributed to steroid-related candidiasis. The VoiSS merits further, prospective validation as a screening
tool for ENT and/or speech and language therapy referral in patients with asthma.
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Introduction
Inhaled asthma medication has the potential to
directly affect the larynx. Therefore, asthma, or its
treatment, may have a direct effect on patients’
voices. Up to 50 per cent of patients using inhaled
corticosteroids may suffer from dysphonia, which is
usually reversible.1 Such dysphonia is usually attribu-
ted to fungal infection or to steroid-induced adductor
myasthenia of the larynx,2 although laryngoscopy or
voice laboratory assessment may reveal more compli-
cated problems such as apposition abnormalities and
cycle-to-cycle irregularity.3,4 Recent work has
demonstrated the impact of dysphonia without sig-
nificant structural laryngeal disease on patients’
quality of life, compared with normal subjects,5 as
measured by the short form 36 (SF-36)
questionnaire. Much of the voice literature is
focused on those patients who attend otolaryngology
clinics; however, Baker et al. found that 50 per cent of
80 young adults with asthma or allergy had vocal
quality abnormalities (as assessed by speech and
language therapists).6 Voice morbidity in patients
with asthma has not been extensively studied.
The voice assessment performed by voice scientists,
speech and language therapists, and others can include
sophisticated perceptual, acoustic, aerodynamic and
endoscopic methods which enable diagnosis and
treatment planning for voice disorders.7 There are a
number of protocols available for perceptual analysis
of the voice, with the grade–roughness–breathiness–
asthenicity–strain (GRBAS) score scale being the
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recognised ‘gold standard’ tool in the UK.8 Speech
and language therapists use this tool to assess a
number of aspects of vocal impairment, using a
four-point scale.9 The tool assesses the voice’s
overall grade (i.e. overall degree of voice deviance),
roughness (i.e. impression of irregular pulses or of
low frequency noise), breathiness (i.e. audible turbu-
lent air leakage), asthenicity and strain. Several
studies have shown reasonable inter-rater reliability
in the use of this scale.10 – 13
It is unclear how the degree of voice impairment
determined by speech and language therapists
relates to patients’ own perceptions. The voice
symptom scale is a 30-item questionnaire which has
been thoroughly evaluated as a tool for the self-
assessment of voice quality.14,15 This scale comprises
a total score plus three robust subscales assessing
voice impairment, emotional reaction and laryngo-
pharyngeal symptoms (i.e. physical component).
The aim of this study was therefore to characterise
the vocal quality and laryngeal appearance in
patients attending a problem asthma clinic, and to
relate this to patients’ and speech and language thera-
pists’ perceptions of vocal morbidity. This evaluation
was conducted in parallel with assessment of upper
airway physiology and nasal disease, the results of
which have been previously reported.16 – 18 A second-
ary aim was to assess the local inter-rater reliability
of the GRBAS scale among speech and language
therapists; these results will be reported separately.
Methods
Patients were recruited to the study from a problem
asthma clinic based in a central teaching hospital.
All patients attending the problem asthma clinic
were eligible for inclusion in the study. Letters of
invitation to take part in the study were sent to
patients attending the clinic, and this invitation was
reinforced by telephone or in person when patients
attended the clinic. The study protocol involved
attendance on a single afternoon. The study was con-
ducted in accordance with the recommendations of
the Helsinki Declaration of 1975, and was approved
by the North Glasgow University Hospitals NHS
Trust local research and ethics committee (REC
reference number 03RE002). All patients gave
written, informed consent for their participation in
the study.
Patients completed the 30-item, self-administered
VoiSS questionnaire. Voice recordings were then
performed in a soundproof booth housed within
the otolaryngology department. Recordings were
made using digital tape recorder and digital audio
tape. Patients were instructed to speak approxi-
mately 10 to 15 cm away from the microphone.
They were asked to speak spontaneously for a few
seconds (giving their name, how they had travelled
to hospital that day, and what they had eaten for
dinner and had watched on television the previous
evening) before reading the standard ‘Rainbow
passage’.19 These recordings were made in the pre-
sence of one of two independent observers who
were not involved in any further data analysis.
Following the topical application of
co-phenylcaine to the nose, each patient had their
larynx and laryngopharynx visualised by a single
observer (KMacK) using standard naso-
laryngoscopic technique. The larynx structure and
function were assessed. Laryngeal appearance was
noted, as was the mobility of the vocal folds on pho-
nation, inspiration and expiration.
The patients’ digital audio tape voice recordings
were transferred onto two compact discs (CDs),
such that both CDs contained every patients’ voice
recording plus anonymised personal details, but in
a different, randomised order. Individual patient’s
recordings therefore corresponded to different indi-
vidual tracks on each CD. A master list was kept in
which track numbers were linked to patient names;
this list was not seen by the voice raters.
The voice raters were three experienced speech
and language therapists familiar with the GRBAS
scale. Raters graded patients’ voices according to
this scale, with a further assessment of voice quality
fluctuation (i.e. instability).20 Each subscale was
assessed on a four-point scale (i.e. zero to three) in
order to determine the degree of vocal impairment.
Each CD was listened to and independently rated
by the three speech and language therapists during
listening sessions at least seven days apart. Every
patient therefore had their voice recording scored
by three speech and language therapists on two
occasions.
The voice symptom score questionnaires were
scored according to the total score and the three sub-
scales of voice impairment (15 items; score range
zero to 60), emotional reaction (eight items; score
range zero to 32) and physical symptoms (seven
items; score range zero to 28). A higher score indi-
cated greater vocal morbidity.
Data analysis
Mean values for each GRBAS(I) scale score were
calculated, from the six scores given by the three
raters, for each patient. The total GRBAS scores
were calculated using the means for each of these
subscales; the mean for the instability subscale was
not used in this calculation as this is not in wide-
spread use. Spearman rank correlations were then
calculated between the GRBAS score subscales
and each VoiSS subscale, as well as the total VoiSS.
Mann–Whitney U tests were used to compare the
VoiSS of subgroups of patients with abnormalities
identified laryngoscopically. MinitabTM software
(version 14; Minitab Inc., Coventry, UK) was used
to perform these calculations. We used conventional
methods to calculate the sensitivity and specificity
and the positive and negative predictive values of
the VoiSS and the GRBAS scores for detecting an
abnormality at laryngoscopy.21
Results
Sixty patients initially agreed to take part in the study
but 17 subsequently withdrew; therefore, 43 patients
were ultimately included. Thirty-four patients had
documented, objective evidence of asthma (i.e.
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significant diurnal variability in peak expiratory
flow rate, significant bronchodilator reversibility or
response of airflow obstruction to oral corticosteroid
trial, or histamine challenge confirming bronchial
hyper-reactivity). Four patients gave a very good
clinical history of asthma from an early age but had
normal lung function whenever this was tested. Five
patients had no definite evidence of asthma. Patients’
median dose of inhaled corticosteroids was 1000 mg
beclomethasone dipropionate or equivalent (inter-
quartile range 800–2000), and all but three patients
were taking inhaled corticosteroids at the time of
assessment.
The VoiSS are shown in Table I. There was no
relationship between VoiSS and inhaled corticoster-
oid dose (r ¼ 0.23; p ¼ 0.117).
The mean of the six GRBAS(I) score assessments
(two each from the three speech and language thera-
pists) was calculated for each patient, to give their
final GRBAS(I) scores (Table II). Thirteen of our
43 (30.2 per cent) patients had an overall grade
score, for the GRBAS scale, of one or more, which
is recognised as denoting definite abnormality. A
statistically significant correlation was observed
between patients’ overall grade score, for the
GRBAS scale, and their inhaled corticosteroid dose
(Spearman r ¼ 0.56; p , 0.001; Figure 1).
Patients’ laryngoscopy results were divided into
structural and functional findings, with each patient
being assessed separately for each category
(Figure 2). Laryngitis was defined as diffuse redden-
ing and swelling of the glottis consistent with an
inflammatory process, and was graded subjectively
as mild, moderate or severe. Only one patient had
laryngeal thrush in addition to mild laryngitis.
Patients with a normal laryngoscopic appearance
had lower median VoiSS than those with abnormal-
ities, as shown in Table III. The mean overall grade
score, for the GRBAS scale, did not differ between
these two groups. However, there were significant
differences in GRBAS subscale scores in the group
with functional abnormalities, compared with those
with no functional abnormalities, as shown in Appen-
dix A (which relates VoiSS and GRBAS(I) subscale
scores to laryngoscopic findings). Spearman Rank cor-
relations between patients’ median GRBAS(I) rating
and their VoiSS (totals and subscale scores) are
shown in Table IV. Nonsignificant p values are not
shown.
Relationship between voice assessment scores and
laryngoscopic appearance
We found that the VoiSS and the GRBAS score pre-
dicted laryngoscopic abnormality equally (Table V).
TABLE I
VOICE SYMPTOM SCORES
Subscale Range Mean (SD) Median (IQR)
Impairment 0–47 15.7 (11.2) 16 (7–20)
Emotional reaction 0–21 3.1 (5.3) 0
Physical symptoms 3–27 11.0 (4.9) 10 (7–14)
Total 3–83 30.5 (18.5) 26 (16–40)
SD ¼ standard deviation; IQR ¼ interquartile range
FIG. 1
Relationship between inhaled corticosteroid dose and overall
grade score for grade–roughness–breathiness–asthenicity–
strain (GRBAS) scale. Spearman r ¼ 0.56; p , 0.001. BDP ¼
beclomethasone dipropionate
FIG. 2
Patients’ laryngoscopy results. Each patient was assessed on
both structural and functional appearance. Other
abnormalities comprised arytenoid abnormality, vocal fold
polyp, and benign thickening of tongue base causing
hypopharyngeal narrowing. Mod ¼ moderate
TABLE II
GRBAS(I) SCORES
Subscale Range Mean (SD) Median (IQR)
Grade 0–2.83 0.59 (0.57) 0.50 (0.17–1.0)
Roughness 0–2.5 0.88 (0.49) 0.83 (0.5–1.17)
Breathiness 0–2.17 0.43 (0.53) 0.33 (0–0.5)
Asthenicity 0–1.5 0.27 (0.36) 0.17 (0–0.5)
Strain 0–2.83 0.62 (0.57) 0.50 (0.17–1.0)
Instability 0–1.83 0.24 (0.38) 0.17 (0–0.33)
Total 0.33–10.83 2.79 (2.1) 2.0 (1.25–3.83)
GRBAS(I)¼ grade–roughness–breathiness–asthenicity–strain–
instability scale; SD¼ standard deviation; IQR¼ interquartile
range
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A total VoiSS of 30 was chosen as a cut-off because
of its relationship with the median total VoiSS for
the study group. An overall grade of one or more
on the GRBAS scale is recognised as identifying sig-
nificant vocal morbidity9 and was therefore used as
the cut-off for this analysis.
Discussion
The patients we studied were representative of
those attending our problem asthma clinic, with a
majority having objective evidence of asthma and
receiving moderately high doses of inhaled corti-
costeroids. We identified voice morbidity as a
problem in this population. While other authors
have investigated the frequency of voice problems
in patients with asthma,2,22 these studies used only
self-administered questionnaires to identify voice
problems. Our study is novel in that it included a
comprehensive vocal assessment undertaken var-
iously by patients (using the VoiSS), by speech
and language therapists (using the GRBAS scale)
and by an ENT specialist (using direct visualisation
of the larynx). Although selection bias may have
operated, the impact of this would have been
diluted by the fact that patients were invited to
take part in a broad-based assessment of their
upper airway (including the nose). Additional data
from a control group would have strengthened our
findings. However, the present research was a pilot
study designed to generate hypotheses. Further
evaluation of the VoiSS and the GRBAS score in
an asthmatic cohort should take into account the
need for a control group. Our analyses of the inter-
relations between VoiSS, GRBAS score and
laryngeal findings were not affected by these
considerations.
A significant proportion of patients had abnormal
laryngeal findings, with abnormalities of function
in 28 per cent (12/43) and laryngitis in 35 per cent
(15/43). Five patients had glottic chinks, a further
five were phonating with the false vocal folds and
two had reduced vocal fold mobility; all these are
likely to affect voice quality. All laryngoscopies
were performed by a single observer; thus, although
consistency was achieved, the impact of recognised
inter-observer variability in the reporting of laryngo-
scopic findings was not assessed.
The VoiSS has been extensively investigated and
refined in over 800 subjects, and its subscales have
shown good internal consistency, in contrast to the
self-administered questionnaires used in earlier
studies of patients with asthma.2,22 Although there
are other instruments available for the self-
assessment of voice quality, such as the vocal handi-
cap index and the voice-related quality of life ques-
tionnaire, we chose the VoiSS because of its
rigorous development process in a UK population,
which included laryngopharyngeal symptom assess-
ment.14,15 Hitherto, there have been no published
VoiSS data for patients with asthma. Our patients’
scores were less abnormal than those reported for
144 functional dysphonics and 145 patients with
structural laryngeal pathology (mean total scores of
43.3 and 46.5, respectively).15 The GRBAS scores
from our study are not readily comparable with
those reported elsewhere, as the latter have been
assessed differently (e.g. using visual analogue
scales)23 or in such a manner as to determine inter-
rater reliability.10
TABLE III
VOISS AND OVERALL GRBAS SCORES, BY LARYNGOSCOPIC APPEARANCE
Laryngoscopy VoiSS GRBAS score
Range Median Range Median
Normal structure & function 4–46 22 0–1.0 0.34
Abnormal structure or function† 3–83 33 0–2.8 0.67
95% CI, difference vs normals 0.0, 21.0‡ 25.0, 0.0
n ¼ 17; †n ¼ 26. ‡p ¼ 0.044; p ¼ 0.15. GRBAS ¼ grade–roughness–breathiness–asthenicity–strain scale; VoiSS ¼
voice symptom score; CI ¼ confidence intervals
TABLE IV
SPEARMAN RANK CORRELATIONS BETWEEN VOISS AND GRBASI SCORE
GRBAS(I) subscale VoiSS subscale
Total Impairment Emotional Physical
Grade 0.24 0.33 (p ¼ 0.034) 0.28 0.05
Roughness 0.08 0.15 0.09 20.09
Breathiness 0.40 (p ¼ 0.008) 0.43 (p ¼ 0.004) 0.38 (p ¼ 0.013) 0.06
Asthenicity 0.47 (p ¼ 0.002) 0.43 (p ¼ 0.004) 0.33 (p ¼ 0.032) 0.15
Strain 0.25 0.30 (p ¼ 0.05) 0.26 0.21
Instability 0.18 0.21 0.14 0.10
Total 0.34 (p ¼ 0.027) 0.38 (p ¼ 0.012) 0.32 (p ¼ 0.036) 0.13
GRBAS(I) ¼ grade–roughness–breathiness–asthenicity–strain–instability scale; VoiSS ¼ voice symptom score
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Higher voice symptom scores were associated with
laryngeal pathology (Table III). We did not evaluate
quality of life, but the emotional domain of the
VoiSS may reflect this parameter. Dysphonia has
been shown to adversely affect patients’ quality of
life;5 in another study, self-rated voice quality was
significantly related to a range of personality, psycho-
logical distress and quality of life measures.24 The
contribution of dysphonia to asthma patients’
impaired quality of life merits further exploration.
. Patients with asthma often complain of voice
symptoms, which are usually attributed to
treatment with inhaled corticosteroids
. Vocal morbidity in patients with asthma is a
complex issue; it can be characterised using
research instruments (e.g. the VoiSS and the
GRBAS score) more routinely used in
non-asthma populations
. In only a small proportion of cases can vocal
morbidity be directly attributed to laryngeal
candidiasis
. The VoiSS is a potential screening tool for
vocal morbidity in patients with asthma
As well as investigating the relationship between
VoiSS responses and laryngoscopic findings, we
also observed a relationship between the specialist,
objective GRBAS scoring and the self-reported, sub-
jective VoiSS. Since the overall grade score for the
GRBAS scale is taken as a summary measure of
voice deviance, we expected to observe a relationship
between this component and the impairment domain
of the VoiSS. We found weakly positive correlations
between the related GRBAS score subscales and the
total GRBAS score, and the VoiSS. The lack of a
relationship between the physical subscale of the
VoiSS and the GRBAS score was expected, as this
subscale assesses non-vocal laryngopharyngeal
symptoms. Murry et al. found a moderate correlation
between total GRBAS score and voice-related
quality of life scores (derived from a 10-item, self-
administered questionnaire).25 This study observed
no breakdown of the relationship with individual
GRBAS score subscales, and it is these, rather than
the total score, which are pertinent to clinical prac-
tice. Our study therefore adds to the evidence that
patients’ perception of vocal morbidity correlates
with that of an experienced observer. In addition,
the overall grade score for the specialist, labour-
intensive GRBAS scale was no better than the
VoiSS in predicting laryngoscopic abnormality
(Table V). For these reasons, we believe that
further validation of the voice symptom score as a
screening test for asthma patients with vocal morbid-
ity is warranted.
We found a low incidence of laryngeal thrush (i.e.
only one patient), suggesting that dysphonia should
not immediately be attributed to this; we also
found little evidence of steroid-induced myopathy
(two patients). Lavy et al. also found a low incidence
of candidiasis in a group of asthmatics complaining of
dysphonia ( four out of 22 patients), and they
identified other laryngoscopic abnormalities (i.e.
mucosal changes, apposition problems and supra-
glottic hyperfunction) which could explain patients’
symptoms.4
Conclusion
We found that laryngeal structural and functional
abnormalities occurred in a significant proportion
of patients attending a problem asthma clinic. We
also found that such abnormalities were associated
with significant differences in patients’ (self-
reported) VoiSS but not in their (more labour-
intensive, objective) GRBAS scores. Very few
patients were found to have fungal infections or myo-
pathy as a result of using inhaled corticosteroids, and
we suggest that vocal morbidity should not be attrib-
uted to these without positive evidence. Our findings
confirm relevant, positive correlations between
VoiSS and GRBAS scores (the latter being our
gold standard measurement), suggesting that these
two instruments measure similar attributes. The
results of this pilot study suggest that the VoiSS is a
useful screening tool in asthma patients; however,
further work is required, as is comparative data for
normal subjects.
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APPENDIX A
RELATION OF VOISS AND GRBAS(I) SCORES TO LARYNGOSCOPIC FINDINGS
Subscale Functional abnormality Structural abnormality
Absent Present p Absent Present p
Mean (SD) Median (IQR) Mean (SD) Median (IQR) Mean (SD) Median (IQR) Mean (SD) Median (IQR)
VoiSS
Impairment 14.7 (11.4) 14 (5–19) 18.3 (10.7) 18 (11.5–26) NS 13.9 (10.0) 13 (5–19) 18.3 (12.5) 16 (10.8–25) NS
Emotional reaction 3.5 (5.8) 0 (0–6) 2.1 (3.7) 1 (0–2.75) NS 1.8 (3.3) 0 (0–2) 4.9 (6.9) 1 (0–9.25) NS
Physical symptoms 11.7 (5.3) 11 (9–15) 8.9 (3.3) 9 (6.25–10.75) NS 10.4 (4.7) 10 (7.5–13) 11.7 (5.3) 11 (7–16.25) NS
Total 30.5 (20.0) 25 (16–40) 30.6 (14.7) 32 (19–39.75) NS 26.7 (13.6) 25 (16–37.5) 35.8 (23.0) 30 (21–49) NS
GRBASI
Grade 0.45 (0.56) 0.17 (0.17–0.68) 0.94 (0.44) 1.00 (0.68–1.13) 0.0015 0.58 (0.49) 0.50 (0.17–1.00) 0.60 (0.68) 0.50 (0.17–0.71) NS
Roughness 0.82 (0.52) 0.83 (0.50–1.17) 1.04 (0.36) 1.00 (1.0–1.29) NS 0.83 (0.46) 0.83 (0.42–1.17) 0.95 (0.53) 1.00 (0.79–1.17) NS
Breathiness 0.31 (0.48) 0.17 (0.00–0.33) 0.72 (0.56) 0.50 (0.33–1.00) 0.0043 0.39 (0.47) 0.33 (0.00–0.42) 0.47 (0.62) 0.25 (0.00–0.75) NS
Asthenicity 0.18 (0.26) 0.00 (0.00–0.33) 0.51 (0.48) 0.42 (0.17–0.83) 0.0154 0.25 (0.37) 0.00 (0.00–0.50) 0.31 (0.36) 0.17 (0.00–0.50) NS
Strain 0.55 (0.60) 0.33 (0.17–0.67) 0.81 (0.47) 0.75 (0.38–1.29) NS 0.61 (0.47) 0.50 (0.25–1.00) 0.64 (0.70) 0.42 (0.17–0.79) NS
Instability 0.19 (0.36) 0.00 (0.00–0.17) 0.39 (0.40) 0.25 (0.17–0.5) 0.0335 0.23 (0.26) 0.17 (0.00–0.33) 0.27 (0.51) 0.00 (0.00–0.33) NS
Total 3.00 (2.90) 1.83 (1.17–4.50) 5.18 (2.67) 4.5 (3.42–7.00) 0.0062 3.55 (2.57) 2.67 (1.25–5.83) 3.69 (3.53) 2.42 (1.50–4.50) NS
GRBAS(I) ¼ grade–roughness–breathiness–asthenicity–strain–instability scale; SD ¼ standard deviation; IQR ¼ interquartile range; VoiSS ¼ voice symptom scale; NS ¼ not significant
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